Pesquisar
Longeveron Inc
LGVNAdicionar à lista de desejos
0.702USD
+0.026+3.88%
Fechamento 07-31 16:00（ET）Cotações atrasadas em 15 min
21.59MValor de mercado
PerdaP/L TTM
Mais detalhes de Longeveron Inc Empresa
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Informações de Longeveron Inc
Código da empresaLGVN
Nome da EmpresaLongeveron Inc
Data de listagemFeb 12, 2021
CEOPowell (Than)
Número de funcionários25
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 12
Endereço1951 NW 7th Ave
CidadeMIAMI
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal33136
Telefone13053027158
Sitehttps://www.longeveron.com/
Código da empresaLGVN
Data de listagemFeb 12, 2021
CEOPowell (Than)
Executivos da empresa Longeveron Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
332.64K
-6.77%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
320.37K
-7.02%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
286.30K
-5.52%
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Executive Chairman of the Board, Co-Founder, Chief Science Officer
Executive Chairman of the Board, Co-Founder, Chief Science Officer
256.46K
+2.07%
Ms. Ursula Ungaro, J.D.
Ms. Ursula Ungaro, J.D.
Independent Director
Independent Director
24.92K
--
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
22.33K
+76.12%
Mr. Roger Joseph Hajjar
Mr. Roger Joseph Hajjar
Independent Director
Independent Director
13.58K
--
Mr. Rock Soffer
Mr. Rock Soffer
Director
Director
--
--
Mr. Paul Lehr, J.D.
Mr. Paul Lehr, J.D.
General Counsel and Secretary
General Counsel and Secretary
--
--
Mr. Than Powell
Mr. Than Powell
Interim Chief Executive Officer
Interim Chief Executive Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
332.64K
-6.77%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
320.37K
-7.02%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
286.30K
-5.52%
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Executive Chairman of the Board, Co-Founder, Chief Science Officer
Executive Chairman of the Board, Co-Founder, Chief Science Officer
256.46K
+2.07%
Ms. Ursula Ungaro, J.D.
Ms. Ursula Ungaro, J.D.
Independent Director
Independent Director
24.92K
--
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
22.33K
+76.12%
Perguntas frequentes
Quem são os cinco principais acionistas de Longeveron Inc?
Os cinco principais acionistas de Longeveron Inc são: Ms. Lisa Locklear
Quantas instituições possuem ações da Longeveron Inc (LGVN)?
Em 2026Q1, 62 instituições possuíam ações da Longeveron Inc, com valor de mercado aproximado de 2.25M, representando 8.08% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 1131825.00.
Qual é a maior fonte de receita da Longeveron Inc?
Em 2026Q1, o segmento de negócios Clinical trial revenue gerou a maior receita para Longeveron Inc, totalizando 954.00K e representando 79.57% da receita total.